Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease$81.9. | February 11, 2022
The message seems clear given recent deSPAC performance and continuing short seller reports SPACs are a yield play and investors shouldn t hold beyond ex-redemption.
So Long SPAC Gamma Squeeze? MEKA Rises in IPO Surprise thestreet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestreet.com Daily Mail and Mail on Sunday newspapers.
Polestar Going Public via Gores/Guggenheim SPAC in $20B Deal thestreet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestreet.com Daily Mail and Mail on Sunday newspapers.
LATN, AMHC Deals Pass, and Joe Ianiello Prices a $265M SPAC IPO thestreet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestreet.com Daily Mail and Mail on Sunday newspapers.